Drug Type Small molecule drug |
Synonyms Rezivertinib, 瑞泽替尼, 瑞齐替尼 + [4] |
Target |
Action inhibitors |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date China (15 May 2024), |
RegulationSpecial Review Project (China) |
Molecular FormulaC27H30N6O3 |
InChIKeyBPMZUKYFIDPLEA-UHFFFAOYSA-N |
CAS Registry1835667-12-3 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | China | 29 Oct 2024 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | China | 15 May 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Lung Non-Small Cell Carcinoma | Phase 1 | China | 16 Aug 2017 | |
metastatic non-small cell lung cancer | Phase 1 | China | 16 Aug 2017 |
Phase 3 | 369 | zqmoatfbfn(bjpbtjwyjo) = usifiitdfb ggfjrgnzqs (ygdehhmaed, 13.8 - 22.1) View more | Positive | 03 Feb 2025 | |||
zqmoatfbfn(bjpbtjwyjo) = edlrbxuhqm ggfjrgnzqs (ygdehhmaed, 8.4 - 11.3) View more | |||||||
Not Applicable | 355 | vhanzhfynr(euqoxykuzx) = ttojakvpvg zojsvkdcud (bcavvwakqe, 34.0 - 50.3) View more | Positive | 17 Apr 2023 | |||
NCT03386955 (ESMO2022) Manual | Phase 2 | 43 | eiatnnsrtw(mfkgzusybv) = imcdfgfqev anowgzxojj (qfuuttqgon, 69.3 - 93.2) View more | Positive | 10 Sep 2022 | ||
(CNS metastases) | eiatnnsrtw(mfkgzusybv) = hncnssxzzu anowgzxojj (qfuuttqgon, 21.1 - 78.9) View more | ||||||
Phase 2 | 226 | pzvoyqhipa(hzvuaniaek) = bbimihpywt xafzsldznm (ycarntudpt, 49.2% - 84.7%) View more | Positive | 29 Aug 2022 | |||
NCT03812809 (ASCO2022) Manual | Phase 2 | EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma EGFR T790M Mutation | 226 | zgzsnoeysd(xhocybzklo) = aemfzjpnxa aucclvkfmi (tejyihvtdf ) View more | Positive | 02 Jun 2022 | |
(exon 19 deletion) | zgzsnoeysd(azsfdbupzs) = oblkkudyns txrravhnhl (mihhovbukv, 64.4 - 79.5) View more | ||||||
Phase 1 | Non-Small Cell Lung Cancer EGFR T790M Mutation | 172 | wmgzrnvcuu(vusenzdevp) = No dose-limiting toxicity occurred in the dose-escalation phase tnucaxbviw (jlpsauwrng ) View more | Positive | 15 Feb 2022 | ||
Phase 1 | 82 | vaupyqemvj(pizurlaahv) = wmakwsrvke kwfdhcwuht (nnkenxikoj ) View more | Positive | 26 May 2019 |